{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:46:14Z","timestamp":1790639174659,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T00:00:00Z","timestamp":1718064000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp & Dohme Ltd","doi-asserted-by":"publisher","award":["MISP#IISP60170"],"award-info":[{"award-number":["MISP#IISP60170"]}],"id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Gobierno de Espa\u00f1a Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["PID2020-119298RB-I00"],"award-info":[{"award-number":["PID2020-119298RB-I00"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.jinf.2024.106204","type":"journal-article","created":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T02:48:36Z","timestamp":1718765316000},"page":"106204","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"title":["Surveillance of invasive pneumococcal disease in Spain exploring the impact of the COVID-19 pandemic (2019-2023)"],"prefix":"10.1016","volume":"89","author":[{"given":"Covadonga","family":"P\u00e9rez-Garc\u00eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9340-6867","authenticated-orcid":false,"given":"Julio","family":"Sempere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2385-2698","authenticated-orcid":false,"given":"Sara","family":"de Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Hita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A\u00edda","family":"\u00dabeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erick Joan","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Llorente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurora","family":"Limia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel Gil","family":"de Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Martin\u00f3n-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0225-607X","authenticated-orcid":false,"given":"Carmen","family":"Ardanuy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0942-8180","authenticated-orcid":false,"given":"Mirian","family":"Domenech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7996-0837","authenticated-orcid":false,"given":"Jose","family":"Yuste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10303","key":"10.1016\/j.jinf.2024.106204_bib1","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S0140-6736(21)00630-9","article-title":"Community-acquired pneumonia","volume":"398","author":"Aliberti","year":"2021","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.jinf.2024.106204_bib2","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/S1473-3099(18)30310-4","article-title":"Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"Collaborators","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"10.1016\/j.jinf.2024.106204_bib3","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa1408544","article-title":"Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults","volume":"372","author":"Bonten","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jinf.2024.106204_bib4","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1093\/cid\/ciab307","article-title":"The evolution and distribution of pneumococcal serotypes in adults hospitalized with community-acquired pneumonia in Spain using a serotype-specific urinary antigen detection test: the CAPA study, 2011-2018","volume":"73","author":"Torres","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.jinf.2024.106204_bib5","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1016\/S2666-5247(21)00064-1","article-title":"Antimicrobial resistance in paediatric Streptococcus pneumoniae isolates amid global implementation of pneumococcal conjugate vaccines: a systematic review and meta-regression analysis","volume":"2","author":"Andrejko","year":"2021","journal-title":"Lancet Microbe"},{"issue":"10","key":"10.1016\/j.jinf.2024.106204_bib6","doi-asserted-by":"crossref","first-page":"e744","DOI":"10.1016\/S2666-5247(22)00127-6","article-title":"Effect of pneumococcal conjugate vaccines and SARS-CoV-2 on antimicrobial resistance and the emergence of Streptococcus pneumoniae serotypes with reduced susceptibility in Spain, 2004-20: a national surveillance study","volume":"3","author":"Sempere","year":"2022","journal-title":"Lancet Microbe"},{"issue":"11","key":"10.1016\/j.jinf.2024.106204_bib7","doi-asserted-by":"crossref","first-page":"e3778","DOI":"10.1093\/cid\/ciaa1483","article-title":"Nationwide trends of invasive pneumococcal disease in Spain from 2009 through 2019 in children and adults during the pneumococcal conjugate vaccine era","volume":"73","author":"de Miguel","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.jinf.2024.106204_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0183191","article-title":"Effectiveness of the 13-valent pneumococcal conjugate vaccine in preventing invasive pneumococcal disease in children aged 7-59 months. A matched case-control study","volume":"12","author":"Dominguez","year":"2017","journal-title":"PLoS One"},{"issue":"37","key":"10.1016\/j.jinf.2024.106204_bib9","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.15585\/mmwr.mm7137a3","article-title":"Use of 15-valent pneumococcal conjugate vaccine among U.S. children: updated recommendations of the Advisory Committee on Immunization Practices \u2013 United States, 2022","volume":"71","author":"Kobayashi","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"4","key":"10.1016\/j.jinf.2024.106204_bib10","doi-asserted-by":"crossref","first-page":"109","DOI":"10.15585\/mmwr.mm7104a1","article-title":"Use of 15-valent pneumococcal conjugate vaccine and 20-valent pneumococcal conjugate vaccine among U.S. adults: updated recommendations of the Advisory Committee on Immunization Practices \u2013 United States, 2022","volume":"71","author":"Kobayashi","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"9","key":"10.1016\/j.jinf.2024.106204_bib11","doi-asserted-by":"crossref","first-page":"e582","DOI":"10.1016\/S2589-7500(23)00108-5","article-title":"Trends in invasive bacterial diseases during the first 2 years of the COVID-19 pandemic: analyses of prospective surveillance data from 30 countries and territories in the IRIS Consortium","volume":"5","author":"Shaw","year":"2023","journal-title":"Lancet Digit Health"},{"issue":"4","key":"10.1016\/j.jinf.2024.106204_bib12","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S1473-3099(18)30052-5","article-title":"Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study","volume":"18","author":"Ladhani","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.jinf.2024.106204_bib13","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S1473-3099(20)30165-1","article-title":"Invasive pneumococcal disease incidence in children and adults in France during the pneumococcal conjugate vaccine era: an interrupted time-series analysis of data from a 17-year national prospective surveillance study","volume":"21","author":"Ouldali","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jinf.2024.106204_bib14","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3389\/fmicb.2020.00309","article-title":"Clinical relevance and molecular pathogenesis of the emerging serotypes 22F and 33F of Streptococcus pneumoniae in Spain","volume":"11","author":"Sempere","year":"2020","journal-title":"Front Microbiol"},{"issue":"6","key":"10.1016\/j.jinf.2024.106204_bib15","doi-asserted-by":"crossref","first-page":"e360","DOI":"10.1016\/S2589-7500(21)00077-7","volume":"3","author":"Brueggemann","year":"2021","journal-title":"Lancet Digit Health"},{"issue":"7","key":"10.1016\/j.jinf.2024.106204_bib16","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/infdis\/jiad028","article-title":"Changes in the incidence of invasive bacterial disease during the COVID-19 pandemic in the United States, 2014-2020","volume":"227","author":"Prasad","year":"2023","journal-title":"J Infect Dis"},{"issue":"7","key":"10.1016\/j.jinf.2024.106204_bib17","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1093\/cid\/ciac100","article-title":"Reemergence of invasive pneumococcal disease in Germany during the spring and summer of 2021","volume":"75","author":"Perniciaro","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.jinf.2024.106204_bib18","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S1473-3099(23)00706-5","article-title":"Invasive pneumococcal disease 3 years after introduction of a reduced 1 + 1 infant 13-valent pneumococcal conjugate vaccine immunisation schedule in England: a prospective national observational surveillance study","volume":"24","author":"Bertran","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"10.1016\/j.jinf.2024.106204_bib19","doi-asserted-by":"crossref","first-page":"e735","DOI":"10.1016\/S2666-5247(22)00158-6","article-title":"Emergence of a multidrug-resistant and virulent Streptococcus pneumoniae lineage mediates serotype replacement after PCV13: an international whole-genome sequencing study","volume":"3","author":"Lo","year":"2022","journal-title":"Lancet Microbe"},{"issue":"9","key":"10.1016\/j.jinf.2024.106204_bib20","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1093\/jac\/dkac199","article-title":"Genomic features of predominant non-PCV13 serotypes responsible for adult invasive pneumococcal disease in Spain","volume":"77","author":"Gonzalez-Diaz","year":"2022","journal-title":"J Antimicrob Chemother"},{"issue":"38","key":"10.1016\/j.jinf.2024.106204_bib21","doi-asserted-by":"crossref","first-page":"5486","DOI":"10.1016\/j.vaccine.2023.07.049","article-title":"Effectiveness of thirteen-valent pneumococcal conjugate vaccine to prevent serotype 3 invasive pneumococcal disease in Quebec in children, Canada","volume":"41","author":"Deceuninck","year":"2023","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.jinf.2024.106204_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007438","article-title":"Global emergence and population dynamics of divergent serotype 3 CC180 pneumococci","volume":"14","author":"Azarian","year":"2018","journal-title":"PLoS Pathog"},{"issue":"7","key":"10.1016\/j.jinf.2024.106204_bib23","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1093\/infdis\/jiaa501","article-title":"Upsurge of conjugate vaccine serotype 4 invasive pneumococcal disease clusters among adults experiencing homelessness in California, Colorado, and New Mexico","volume":"223","author":"Beall","year":"2021","journal-title":"J Infect Dis"},{"issue":"7","key":"10.1016\/j.jinf.2024.106204_bib24","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.3201\/eid2707.204403","article-title":"Whole-genome analysis of Streptococcus pneumoniae serotype 4 causing outbreak of invasive pneumococcal disease, Alberta, Canada","volume":"27","author":"Kellner","year":"2021","journal-title":"Emerg Infect Dis"},{"issue":"7","key":"10.1016\/j.jinf.2024.106204_bib25","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.vaccine.2021.10.046","article-title":"International links between Streptococcus pneumoniae vaccine serotype 4 sequence type (ST) 801 in Northern European shipyard outbreaks of invasive pneumococcal disease","volume":"40","author":"Gladstone","year":"2022","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.jinf.2024.106204_bib26","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1093\/jac\/dkab482","article-title":"A national longitudinal study evaluating the activity of cefditoren and other antibiotics against non-susceptible Streptococcus pneumoniae strains during the period 2004-20 in Spain","volume":"77","author":"Sempere","year":"2022","journal-title":"J Antimicrob Chemother"},{"issue":"16","key":"10.1016\/j.jinf.2024.106204_bib27","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2020.25.16.1900457","article-title":"Two multi-fragment recombination events resulted in the beta-lactam-resistant serotype 11A-ST6521 related to Spain9V-ST156 pneumococcal clone spreading in south-western Europe, 2008 to 2016","volume":"25","author":"Gonzalez-Diaz","year":"2020","journal-title":"Eur Surveill"},{"issue":"19","key":"10.1016\/j.jinf.2024.106204_bib28","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1016\/j.vaccine.2023.04.008","volume":"41","author":"Kawade","year":"2023","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.jinf.2024.106204_bib29","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S1473-3099(23)00061-0","article-title":"Efficacy against pneumococcal carriage and the immunogenicity of reduced-dose (0 + 1 and 1 + 1) PCV10 and PCV13 schedules in Ho Chi Minh City, Viet Nam: a parallel, single-blind, randomised controlled trial","volume":"23","author":"Temple","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"10.1016\/j.jinf.2024.106204_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002845","article-title":"Estimated impact of revising the 13-valent pneumococcal conjugate vaccine schedule from 2+1 to 1+1 in England and Wales: a modelling study","volume":"16","author":"Choi","year":"2019","journal-title":"PLoS Med"},{"issue":"2","key":"10.1016\/j.jinf.2024.106204_bib31","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S1473-3099(22)00526-6","article-title":"Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1\/2, randomised, double-blind, active comparator-controlled, multicentre, US-based trial","volume":"23","author":"Platt","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"31","key":"10.1016\/j.jinf.2024.106204_bib32","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1016\/j.vaccine.2022.05.079","article-title":"Phase 1\/2 study of a novel 24-valent pneumococcal vaccine in healthy adults aged 18 to 64 years and in older adults aged 65 to 85 years","volume":"40","author":"Chichili","year":"2022","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.jinf.2024.106204_bib33","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3390\/vaccines9020186","article-title":"Vaccination with LytA, LytC, or Pce of Streptococcus pneumoniae protects against sepsis by inducing IgGs that activate the complement system","volume":"9","author":"Corsini","year":"2021","journal-title":"Vaccines"},{"issue":"50","key":"10.1016\/j.jinf.2024.106204_bib34","doi-asserted-by":"crossref","first-page":"6148","DOI":"10.1016\/j.vaccine.2016.11.001","article-title":"Immunization with LytB protein of Streptococcus pneumoniae activates complement-mediated phagocytosis and induces protection against pneumonia and sepsis","volume":"34","author":"Corsini","year":"2016","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.jinf.2024.106204_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines9030187","article-title":"Immunization with SP_1992 (DiiA) protein of Streptococcus pneumoniae reduces nasopharyngeal colonization and protects against invasive disease in mice","volume":"9","author":"Martin-Galiano","year":"2021","journal-title":"Vaccines"},{"issue":"2","key":"10.1016\/j.jinf.2024.106204_bib36","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3390\/vaccines9020181","article-title":"Pneumococcal choline-binding proteins involved in virulence as vaccine candidates","volume":"9","author":"Sempere","year":"2021","journal-title":"Vaccines"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445324001385?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445324001385?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T03:38:10Z","timestamp":1763177890000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445324001385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S0163445324001385"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2024.106204","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Surveillance of invasive pneumococcal disease in Spain exploring the impact of the COVID-19 pandemic (2019-2023)","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2024.106204","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of The British Infection Association.","name":"copyright","label":"Copyright"}],"article-number":"106204"}}